Nearly a decade of waiting could end for British families struggling with rising rates of childhood myopia. A groundbreaking UK clinical trial published in The BMJ confirms that low-concentration atropine eye drops—a treatment already used worldwide—are safe and effective enough to offer real hope for slowing short-sightedness in children, marking a potential turning point in how the NHS approaches this rapidly growing eye condition.
Myopia in children is escalating globally at an alarming rate, burdened by rising healthcare costs and the threat of long-term eye complications in adulthood. The condition has long posed a puzzle for UK policymakers: while doctors elsewhere successfully deployed atropine eye drops to slow myopia progression, these drops were simply not available through the NHS, leaving British parents and clinicians without access to a treatment option that had proven track records internationally. The CHAMP-UK trial—a multicentre, placebo-controlled study—was designed to fill precisely this knowledge gap and determine whether the treatment would work safely in the UK context.
Researchers recruited 289 children aged 6 to 12 years (average age 9.3 years) from five NHS hospital eye services between June 2019 and February 2022, tracking them for two years. Of these, 192 children received daily 0.01% atropine eye drops while 97 received placebo, all while wearing standard corrective spectacles. After two years of monitoring every six months, results from 230 children revealed encouraging findings. Children using atropine experienced an average reduction of 0.38 diopters in refractive error and 0.14 millimeters in central axial length—the two critical measures of myopia progression—compared to those on placebo. While the researchers acknowledge these are "small" improvements, they represent meaningful progress in a field where every fraction of a diopter matters over a lifetime of vision.
The trial's safety profile was equally reassuring. There were no significant differences in adverse events between the atropine and placebo groups. Side effects such as sore eyes, blurry vision, itchiness, and difficulty reading or writing—concerns that might have complicated treatment in younger children—occurred with equal frequency in both groups. The only notable physiological change was a slightly larger pupil diameter in children using atropine, a 0.36 millimeter difference that posed no practical problems.
The researchers emphasize their conclusion carefully: low-concentration atropine eye drops represent "a worthwhile addition to currently available optical interventions for the treatment of myopia in children in the UK." This phrasing reflects a measured optimism grounded in evidence rather than oversized promises. They acknowledge trial limitations, including questions about how these results would translate beyond a clinical research setting and the unavoidable influence of the COVID-19 pandemic, which occurred during the study period.
With myopia rates climbing in children across the UK as elsewhere, this validation opens a real door for policymakers and the NHS to consider expanding treatment options. For families watching their children's eyesight worsen year after year, and for the clinicians who have watched other countries benefit from this approach, the trial offers something precious: evidence-based permission to bring an established treatment home.